
- Oncology NEWS International Vol 16 No 5
- Volume 16
- Issue 5
AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
over 18 years ago
Escalating Drug Costs Could Provoke Consumer Backlashover 18 years ago
Large Study Casts Doubt on Value of CADover 18 years ago
Cetuximab Does Not Increase Mucositis in H&N Cancerover 18 years ago
2004 Update Shows Continued Lower Breast Ca Incidenceover 18 years ago
Reclast Single-Dose Infusion Approved for Paget's Diseaseover 18 years ago
Fragmin Approved for VTE in Cancer Ptsover 18 years ago
New Phase III Trial of Genasense in Advanced Melanoma Plannedover 18 years ago
Cervical Cancer Vaccines Show Sustained Protectionover 18 years ago
The 'New' Medicare: Passive Payer No More; PQRI Is First StepNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































